Frontline NALIRIFOX Approved by FDA in Metastatic PDAC

News
Article

Patients with metastatic pancreatic ductal adenocarcinoma may now receive irinotecan liposome in combination with 5-fluorouracil/leucovorin and oxaliplatin in the first-line setting, which has been approved by the FDA.

The approval is based on results from the phase 3 NAPOLI 3 trial (NCT04083235), which analyzed NALIRIFOX vs nab-paclitaxel and gemcitabine in metastatic pancreatic adenocarcinoma.

The approval is based on results from the phase 3 NAPOLI 3 trial (NCT04083235), which analyzed NALIRIFOX vs nab-paclitaxel and gemcitabine in metastatic pancreatic adenocarcinoma.

The News

The FDA has approved irinotecan liposome (Onivyde) in combination with 5-fluorouracil/leucovorin (5-FU) and oxaliplatin (NALIRIFOX) as first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC).1

 

Supporting Data

The approval is based on results from the phase 3 NAPOLI 3 trial (NCT04083235), which analyzed NALIRIFOX vs nab-paclitaxel and gemcitabine for patients in the aforementioned population.2 Results were previously presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.3 

The median follow-up was 16.1 months, and the median overall survival (OS) was 11.1 months (95% CI, 10.0-12.1) in the NALIRIFOX group vs 9.2 months (95% CI, 8.3-10.6) in the nab-paclitaxel/gemcitabine group (HR, 0.83; 95% CI, 0.70-0.99; P = .036).2 At 12 months, the OS rate was 45.6% (95% CI, 40.5%-50.5%) and 39.5% (95% CI, 34.6%-44.4%) between both groups, respectively. The OS rate at 18 months in the NALIRIFOX group was 26.2% (95% CI, 20.9%-31.7%) vs 19.3% (95% CI, 14.8%-24.2%) in the comparator arm.

The median progression-free survival (PFS) was 7.4 months (95% CI, 6.0-7.7) in the NALIRIFOX group and 5.6 months (95% CI, 5.3-5.8) in the nab-paclitaxel/gemcitabine group (HR, 0.69; 95% CI, 0.58-0.83; P <.0001). At 12 months, the PFS rate was 27.4% (95% CI, 22.3%-32.7%) vs 13.9% (95% CI, 9.7%-18.9%), and at 18 months it was 11.4% (95% CI, 7.1%-16.9%) vs 3.6% (95% CI, 0.5%-12.3%) between each respective arm.

An objective response was observed in 42% of patients in the NALIRIFOX group vs 36% in the comparator arm (P = .11). Patients had a median duration of response of 7.3 months (95% CI, 5.8-7.6) and 5.0 months (95% CI, 3.8-5.6) between both groups, respectively (HR, 0.67; 95% CI, 0.48-0.93).

NAPOLI 3 Trial Design

A total of 770 patients were randomly assigned 1:1 to receive a continuous intravenous infusion of 50 mg/m2 of liposomal irinotecan, 60 mg/m2 of oxaliplatin, 400 mg/m2 of leucovorin, and 2400 mg/m2 of fluorouracil over 46 hours on days 1 and 15; or 125 mg/m2 of nab-paclitaxel and 1000 mg/m2 of gemcitabine given intravenously on days 1, 8, and 15 of a 28-day cycle. After permanent discontinuation of treatment, patients had a 30-day follow-up and then a long-term follow-up conducted every 2 months. Long-term follow-up included monitoring of survival status, loss to follow-up, withdrawal, or study closure.

The primary end point was OS, with secondary end points including PFS and ORR.

Safety Data

The median duration of treatment was 24.3 weeks with a median of 5 cycles in the NALIRIFOX group and 17.6 weeks with a median of 4 cycles in the comparator arm. Dose reductions occurred in 60% vs 54% in each group, respectively.

More than 99% of patients had treatment-emergent adverse effects (TEAEs) in the NALIRIFOX arm compared with 99% in the comparator arm. The most common TEAEs in each respective arm included diarrhea (20% vs 5%), nausea (12% vs 3%), decreased appetite (9% vs 3%), and vomiting (7% vs 2%).

TEAEs leading to discontinuation occurred in 32% of patients in the NALIRIFOX arm vs 30% in the comparator arm. Dose reductions due to TEAEs occurred in 56% vs 50%, serious TEAEs occurred in 54% vs 52%, and TEAEs leading to death occurred in 6% vs 6% between both respective arms.

The FDA accepted the supplemental new drug application for NALIRIFOX in metastatic PDAC in June 2023.4

References

  1. FDA approves irinotecan liposome for first-line treatment of metastatic pancreatic adenocarcinoma. News release. FDA. February 13, 2024. Accessed February 13, 2024. https://bit.ly/3HXITdz
  2. Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272-1281. doi:10.1016/S0140-6736(23)01366-1
  3. O’Reilly EM, Melisi D, Macarulla T, et al. Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial. J Clin Oncol. 2023;41(suppl 16):4006. doi:10.1200/JCO.2023.41.16_suppl.4006
  4. Ipsen announces U.S. FDA submission acceptance of its supplemental new drug application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma. News release. Ipsen. June 14, 2023. Accessed January 18, 2024. http://tinyurl.com/442ck4uy
Recent Videos
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
Milad Baradaran, PhD, DABR, outlines the design of Mobetron as an option for administering intraoperative radiation therapy in pancreatic cancer care.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Related Content